These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 32819262

  • 1. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors.
    Subrahmanyan NA, Koshy RM, Jacob K, Pappachan JM.
    Curr Drug Saf; 2021; 16(2):154-164. PubMed ID: 32819262
    [Abstract] [Full Text] [Related]

  • 2. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
    Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K.
    Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
    [Abstract] [Full Text] [Related]

  • 3. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 4. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ.
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [Abstract] [Full Text] [Related]

  • 5. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

  • 6. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
    Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF.
    Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ.
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [Abstract] [Full Text] [Related]

  • 8. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.
    Deacon CF, Lebovitz HE.
    Diabetes Obes Metab; 2016 Apr; 18(4):333-47. PubMed ID: 26597596
    [Abstract] [Full Text] [Related]

  • 9. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, Green JB, Ruff CT, Sabatine MS.
    Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
    [Abstract] [Full Text] [Related]

  • 10. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F.
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [Abstract] [Full Text] [Related]

  • 11. Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors.
    Ryan G.
    Postgrad Med; 2015 May; 127(8):842-54. PubMed ID: 26436470
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ.
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [Abstract] [Full Text] [Related]

  • 13. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
    Guo WQ, Li L, Su Q, Dai WR, Ye ZL.
    Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
    [Abstract] [Full Text] [Related]

  • 14. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K, Gräber S.
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [Abstract] [Full Text] [Related]

  • 15. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 16. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P.
    Clin Ther; 2014 Dec 01; 36(12):2072-2079. PubMed ID: 25453730
    [Abstract] [Full Text] [Related]

  • 17. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
    Wang B, Sun Y, Sang Y, Liu X, Liang J.
    Medicine (Baltimore); 2018 Nov 01; 97(46):e12633. PubMed ID: 30431561
    [Abstract] [Full Text] [Related]

  • 18. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
    Santamarina M, Carlson CJ.
    BMC Cardiovasc Disord; 2019 Mar 15; 19(1):60. PubMed ID: 30876392
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E, Monami M.
    Adv Ther; 2017 Jan 15; 34(1):1-40. PubMed ID: 27844335
    [Abstract] [Full Text] [Related]

  • 20. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun 15; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.